Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments
Abstract: Organotypic and microphysiological systems (MPS) that can emulate the molecular phenotype and function of human tissues, such as liver, are increasingly used in preclinical drug development. However, despite their improved predictivity, drug development success rates have remained low with most compounds failing in clinical phases despite promising preclinical data. Here, it is tested whether absorption of small molecules to polymers commonly used for MPS fabrication can impact preclinical pharmacological and toxicological assessments and contribute to the high clinical failure rates. To this end, identical devices are fabricated from eight different MPS polymers and absorption of prototypic compounds with different physicochemical properties are analyzed. It is found that overall absorption is primarily driven by compound hydrophobicity and the number of rotatable bonds. However, absorption can differ by >1000‐fold between polymers with polydimethyl siloxane (PDMS) being most absorptive, whereas polytetrafluoroethylene (PTFE) and thiol‐ene epoxy (TEE) absorbed the least. Strikingly, organotypic primary human liver cultures successfully flagged hydrophobic hepatotoxins in lowly absorbing TEE devices at therapeutically relevant concentrations, whereas isogenic cultures in PDMS devices are resistant, resulting in false negative safety signals. Combined, these results can guide the selection of MPS materials and facilitate the development of preclinical assays with improved translatability.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments ; day:10 ; month:12 ; year:2023 ; extent:13
Advanced healthcare materials ; (10.12.2023) (gesamt 13)
- Creator
-
Kemas, Aurino M.
Zandi Shafagh, Reza
Taebnia, Nayere
Michel, Maurice
Preiss, Lena
Hofmann, Ute
Lauschke, Volker Martin
- DOI
-
10.1002/adhm.202303561
- URN
-
urn:nbn:de:101:1-2023121114122880200058
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:30 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kemas, Aurino M.
- Zandi Shafagh, Reza
- Taebnia, Nayere
- Michel, Maurice
- Preiss, Lena
- Hofmann, Ute
- Lauschke, Volker Martin
Other Objects (12)
Emerging Neuroblastoma 3D In Vitro Models for Pre-Clinical Assessments
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
High-throughput high-volume nuclear imaging for preclinical in vivo compound screening§
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
Preclinical Safety and Efficacy Assessments for Novel Femtosecond Lasers in Corneal Refractive Surgery
Dry powder inhaled compound delivery for early pre-clinical in vivo efficacy studies
Inter-compound and Intra-compound Global Sensitivity Analysis of a Physiological Model for Pulmonary Absorption of Inhaled Compounds
Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease
Compound flood impact forecasting: integrating fluvial and flash flood impact assessments into a unified system
Compound Ethnicity, Compound Identity
Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion
Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension
Emerging Neuroblastoma 3D In Vitro Models for Pre-Clinical Assessments
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
High-throughput high-volume nuclear imaging for preclinical in vivo compound screening§
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
Preclinical Safety and Efficacy Assessments for Novel Femtosecond Lasers in Corneal Refractive Surgery
Dry powder inhaled compound delivery for early pre-clinical in vivo efficacy studies
Inter-compound and Intra-compound Global Sensitivity Analysis of a Physiological Model for Pulmonary Absorption of Inhaled Compounds
Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease
Compound flood impact forecasting: integrating fluvial and flash flood impact assessments into a unified system
Compound Ethnicity, Compound Identity
Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion
Overexpression of P-glycoprotein, MRP2, and CYP3A4 impairs intestinal absorption of octreotide in rats with portal hypertension
Emerging Neuroblastoma 3D In Vitro Models for Pre-Clinical Assessments
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
High-throughput high-volume nuclear imaging for preclinical in vivo compound screening§
Preclinical characterization of the myxobacterial compound pretubulysin as novel vascular disrupting agent
Preclinical Safety and Efficacy Assessments for Novel Femtosecond Lasers in Corneal Refractive Surgery
Dry powder inhaled compound delivery for early pre-clinical in vivo efficacy studies
Inter-compound and Intra-compound Global Sensitivity Analysis of a Physiological Model for Pulmonary Absorption of Inhaled Compounds
Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease
Compound flood impact forecasting: integrating fluvial and flash flood impact assessments into a unified system
Compound Ethnicity, Compound Identity
Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion